Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC 1 national cross-sectional study

Autor: Mercader-García P, Pastor-Nieto MA, Gonzalez-Perez R, Cordoba-Guijarro S, Jimenez-Arnau AM, Ruiz-Gonzalez I, Mora-Fernández V, Miquel J, Silvestre-Salvador JF, Ortiz-Frutos FJ, Sanz-Sanchez T, Rodriguez-Serna M, Perez-Feal P, Sánchez-Pérez J, Heras-Mendaza F, Serra-Baldrich E, Zaragoza-Ninet V, Hervella-Garces M, Gatica-Ortega ME, García-Doval I, Descalzo MÁ, Borrego L
Rok vydání: 2021
Předmět:
Zdroj: Contact Dermatitis
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
ISSN: 0105-1873
Popis: Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of the 2000's. In 2008 this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN progressively decreased. Despite that gradual decline, it is still patch-tested in most baseline series. This study assesses the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients as well as the relevance of positive patch tests in a nationwide Spanish registry (REIDAC).
Databáze: OpenAIRE
Externí odkaz: